Literature DB >> 30803969

Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.

Rima K Acosta1, Madeleine Willkom2, Ross Martin2, Silvia Chang2, Xuelian Wei2, William Garner2, Justin Lutz2, Sophia Majeed2, Devi SenGupta2, Hal Martin2, Erin Quirk2, Kirsten L White2.   

Abstract

In clinical studies GS-US-380-1489 (study 1489) and GS-US-380-1490 (study 1490), bictegravir-emtricitabine-tenofovir alafenamide (B-F-TAF), dolutegravir-abacavir-lamivudine (DTG-ABC-3TC), and dolutegravir plus emtricitabine-tenofovir alafenamide (DTG+F-TAF) treatment achieved high rates of virologic suppression in HIV-1 treatment-naive participants through week 48. Preexisting primary drug resistance was present at levels of 1.3% integrase strand transfer inhibitor resistance (INSTI-R), 2.7% nucleoside reverse transcriptase inhibitor resistance (NRTI-R), 14.1% nonnucleoside reverse transcriptase inhibitor resistance (NNRTI-R), and 3.5% protease inhibitor resistance (PI-R) in the 1,274 participants from these studies. These mutations did not affect treatment outcomes. Resistance analyses in 13 virologic failures found no emergent resistance to study drugs.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  bictegravir; clinical trial; resistance; treatment naive

Mesh：

Substances：

Year:  2019        PMID： 30803969      PMCID： PMC6496090          DOI： 10.1128/AAC.02533-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir.

Authors:  Vici Varghese; Tommy F Liu; Soo-Yon Rhee; Paolo Libiran; Christina Trevino; W Jeffrey Fessel; Robert W Shafer
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-21       Impact factor: 2.205

2.  ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL.

Authors:  Babafemi O Taiwo; Lu Zheng; Andrei Stefanescu; Amesika Nyaku; Baiba Bezins; Carole L Wallis; Catherine Godfrey; Paul E Sax; Edward Acosta; David Haas; Kimberly Y Smith; Beverly Sha; Cornelius Van Dam; Roy M Gulick
Journal:  Clin Infect Dis       Date:  2018-05-17       Impact factor: 9.079

3.  Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

Authors:  Pedro Cahn; Anton L Pozniak; Horacio Mingrone; Andrey Shuldyakov; Carlos Brites; Jaime F Andrade-Villanueva; Gary Richmond; Carlos Beltran Buendia; Jan Fourie; Moti Ramgopal; Debbie Hagins; Franco Felizarta; Jose Madruga; Tania Reuter; Tamara Newman; Catherine B Small; John Lombaard; Beatriz Grinsztejn; David Dorey; Mark Underwood; Sandy Griffith; Sherene Min
Journal:  Lancet       Date:  2013-07-03       Impact factor: 79.321

4.  Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.

Authors:  Catherine Orrell; Debbie P Hagins; Elena Belonosova; Norma Porteiro; Sharon Walmsley; Vicenç Falcó; Choy Y Man; Alicia Aylott; Ann M Buchanan; Brian Wynne; Cindy Vavro; Michael Aboud; Kimberly Y Smith
Journal:  Lancet HIV       Date:  2017-07-17       Impact factor: 12.767

5.  Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.

Authors:  Diane E Bennett; Ricardo J Camacho; Dan Otelea; Daniel R Kuritzkes; Hervé Fleury; Mark Kiuchi; Walid Heneine; Rami Kantor; Michael R Jordan; Jonathan M Schapiro; Anne-Mieke Vandamme; Paul Sandstrom; Charles A B Boucher; David van de Vijver; Soo-Yon Rhee; Tommy F Liu; Deenan Pillay; Robert W Shafer
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

6.  Human immunodeficiency virus reverse transcriptase and protease sequence database.

Authors:  Soo-Yon Rhee; Matthew J Gonzales; Rami Kantor; Bradley J Betts; Jaideep Ravela; Robert W Shafer
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

7.  Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.

Authors:  Bonaventura Clotet; Judith Feinberg; Jan van Lunzen; Marie-Aude Khuong-Josses; Andrea Antinori; Irina Dumitru; Vadim Pokrovskiy; Jan Fehr; Roberto Ortiz; Michael Saag; Julia Harris; Clare Brennan; Tamio Fujiwara; Sherene Min
Journal:  Lancet       Date:  2014-04-01       Impact factor: 79.321

8.  HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins.

Authors:  Zabrina L Brumme; Mina John; Jonathan M Carlson; Chanson J Brumme; Dennison Chan; Mark A Brockman; Luke C Swenson; Iris Tao; Sharon Szeto; Pamela Rosato; Jennifer Sela; Carl M Kadie; Nicole Frahm; Christian Brander; David W Haas; Sharon A Riddler; Richard Haubrich; Bruce D Walker; P Richard Harrigan; David Heckerman; Simon Mallal
Journal:  PLoS One       Date:  2009-08-19       Impact factor: 3.240

9.  Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.

Authors:  Joel Gallant; Adriano Lazzarin; Anthony Mills; Chloe Orkin; Daniel Podzamczer; Pablo Tebas; Pierre-Marie Girard; Indira Brar; Eric S Daar; David Wohl; Jürgen Rockstroh; Xuelian Wei; Joseph Custodio; Kirsten White; Hal Martin; Andrew Cheng; Erin Quirk
Journal:  Lancet       Date:  2017-08-31       Impact factor: 79.321

10.  Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.

Authors:  Tomas Doyle; David T Dunn; Francesca Ceccherini-Silberstein; Carmen De Mendoza; Frederico Garcia; Erasmus Smit; Esther Fearnhill; Anne-Genevieve Marcelin; Javier Martinez-Picado; Rolf Kaiser; Anna Maria Geretti
Journal:  J Antimicrob Chemother       Date:  2015-08-26       Impact factor: 5.790
View more
  7 in total

1.  Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.

Authors:  Philip L Tzou; Soo-Yon Rhee; Diane Descamps; Dana S Clutter; Bradley Hare; Orna Mor; Maxime Grude; Neil Parkin; Michael R Jordan; Silvia Bertagnolio; Jonathan M Schapiro; P Richard Harrigan; Anna Maria Geretti; Anne-Geneviève Marcelin; Robert W Shafer
Journal:  J Antimicrob Chemother       Date:  2020-01-01       Impact factor: 5.790

2.  Navigating Human Immunodeficiency Virus Screening Recommendations for People on Pre-Exposure Prophylaxis and the Need to Update Testing Algorithms.

Authors:  Eric A Meyerowitz; Raffaele M Bernardo; Michelle D Collins-Ogle; Jonathan M Czeresnia; Cariane M Matos; Caroline Mullis; Heather B Root; Julián A Torres-Isasiga; Helen Tsai; Barry S Zingman
Journal:  Open Forum Infect Dis       Date:  2022-04-15       Impact factor: 4.423

3.  Surveillance of HIV-1 transmitted integrase strand transfer inhibitor resistance in the UK.

Authors:  Jean L Mbisa; Juan Ledesma; Peter Kirwan; David F Bibby; Carmen Manso; Andrew Skingsley; Gary Murphy; Alison Brown; David T Dunn; Valerie Delpech; Anna Maria Geretti
Journal:  J Antimicrob Chemother       Date:  2020-11-01       Impact factor: 5.790

Review 4.  Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs.

Authors:  Steven J Smith; Xue Zhi Zhao; Dario Oliveira Passos; Dmitry Lyumkis; Terrence R Burke; Stephen H Hughes
Journal:  Viruses       Date:  2021-01-29       Impact factor: 5.048

5.  Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial.

Authors:  Franco Maggiolo; Giuliano Rizzardini; Jean-Michel Molina; Federico Pulido; Stephane De Wit; Linos Vandekerckhove; Juan Berenguer; Michelle L D'Antoni; Christiana Blair; Susan K Chuck; David Piontkowsky; Hal Martin; Richard Haubrich; Ian R McNicholl; Joel Gallant
Journal:  Infect Dis Ther       Date:  2021-03-09

6.  Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.

Authors:  Michelle L D'Antoni; Kristen Andreatta; Rima Acosta; Hal Martin; Silvia Chang; Ross Martin; Kirsten L White
Journal:  J Acquir Immune Defic Syndr       Date:  2022-04-01       Impact factor: 3.771

7.  Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China.

Authors:  Fengting Yu; Qun Li; Linghang Wang; Hongxin Zhao; Hao Wu; Siyuan Yang; Yunxia Tang; Jiang Xiao; Fujie Zhang
Journal:  Pharmgenomics Pers Med       Date:  2022-03-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.